

CLAIMS

The following **Listing of Claims** will replace all prior versions, and listings, of claims in the application.

Listing of Claims:

- 1-2. (canceled)
3. (currently amended) A method of selecting GGTA1 null cells comprising the steps of:
 - (a) obtaining a line of cells obtained from a GGTA1 heterozygous pig or fetus;
 - (b) enriching the cells for GGTA1 null cells by treating the cells with agents that specifically bind an $\alpha(1,3)$ -galactose epitope and that deplete cells that express the epitope without drug selection; and
 - (c) scanning the line for a viable GGTA1 null cell.
4. (original) The method of claim 3 wherein in step (b), the cells are enriched by at least one treatment selected from the group consisting of: (a) treating the said cells with anti-galactose- $\alpha(1,3)$ -galactose antibodies, in the presence of complement; (b) depleting the said cells with magnetic micro-beads bound with anti-gal reagents; (c) treating the said cells with anti-galactose- $\alpha(1,3)$ -galactose antibodies and depleting the said cells with magnetic micro-beads bound with anti-antibodies; and (d) treating the said line with gal epitope ligands and depleting the said line with magnetic micro-beads bound with anti ligand antibodies.
5. (original) The method of claim 3 wherein in step (b), the cells are enriched by multiple treatments selected from the group consisting of: (a) treating the said cells with anti-galactose- $\alpha(1,3)$ -galactose antibodies, in the presence of complement; (b) depleting the said cells with magnetic micro-beads bound with anti-gal reagents; (c) treating the said cells with anti-galactose- $\alpha(1,3)$ -galactose antibodies and depleting the said cells with magnetic micro-beads bound with anti-antibodies; and (d) treating the said cells with gal epitope ligands and depleting the said line with magnetic micro-beads bound with anti ligand antibodies.

6. (original) The method of claim 3 wherein in step (b), the cells are enriched by three treatments of each of the following: (a) treating the said cells with anti-galactose- α (1,3)-galactose antibodies, in the presence of complement; (b) treating the said cells with gal epitope ligands and depleting the said line with magnetic micro-beads bound with anti ligand antibodies.
7. (original) The method according to any of claims 3-6 wherein the line of cells is a line of porcine fetal fibroblast cells.
8. (original) The method according to any of claims 3-6 wherein the line of cells is a clonal population of porcine fetal fibroblast cells.
9. (original) The method of claim 7 wherein the porcine fetal fibroblast cells originate from miniature swine.
10. (original) The method according to claim any of claims 3-6 wherein the line of cells is a line of stem cells.
11. (original) The method of claim 10 wherein the stem cells are primordial stem cells.
12. (original) The method according to any of claims 4-6 wherein the anti-galactose- α (1,3)-galactose antibodies are primate antibodies.
13. (original) The method according to any of claims 4-6 wherein the anti-galactose- α (1,3)-galactose antibodies are monoclonal antibodies or fragments thereof.
14. (original) The method according to any of claims 4-5, wherein the anti-gal reagents are selected from a group consisting of anti-galactose- α (1,3)-galactose antibodies and lectin.

15. (original) The method according to any of 4-6, wherein the gal epitope ligands are IB4 conjugates and the anti-epitope ligands are anti-IB4 conjugates.

16. (original) The method according to claim 15 wherein the IB4 conjugates are selected from a group consisting of IB4 biotin and IB4-FITC and the anti-IB4 conjugates are selected from a group consisting of anti-biotin and anti-FITC.

17-42. (canceled)

43. (original) The method of claim 8 wherein the porcine fetal fibroblast cells originate from miniature swine.

44. (canceled)